Inhibition of hyaluronic acid degradation pathway suppresses glioma progression by inducing apoptosis and cell cycle arrest

Tao Yan, Yang He, Caixia Xu, Junsi Liu, Yun Meng, Qing Jiang, Jinxing Li, Guiqiong Kang, Liangjian Zhou, Shuai Xiao, Yanpeng Xue, Jiayi Xu, Xin Chen, Fengyuan CheCancer 2023 · DOI

Abstract

Collectively, these observations suggest that HYAL2 overexpression could promote glioma progression. Thus, treatments that disrupt HA catabolism by altering HYAL2 expression may serve as effective strategies for glioma treatment.

Introduction

Gliomas are notorious for their high mortality rates and resistance to standard treatments like surgery and chemotherapy. A defining characteristic of the glioma microenvironment is the abundance of hyaluronic acid (HA). While previous research has largely focused on how the synthesis of HA facilitates tumor growth, the role of its catabolism (breakdown) has remained less clear. In many cancers, the fragments produced when HA is degraded—low-molecular-weight HA—promote inflammation and tumor spreading. This study investigates which enzymes are responsible for this degradation in glioma and whether inhibiting them can halt disease progression.

Methods

The researchers employed a multi-layered approach combining bioinformatic analysis with experimental validation:

  • Bioinformatics: They screened the expression of six hyaluronidases (HYAL1-4, HYALP1, and SPAM1) across thousands of patient samples in the TCGA and CGGA databases.
  • In Vitro Validation: Expression levels were confirmed in four glioma cell lines (U251, LN229, U87, A172) and compared against healthy vascular cells (HUVECs).
  • Functional Assays: The team used siRNA knockdown to silence the HYAL2 gene and measured the impact on cell viability, proliferation (EdU and colony formation), and programmed cell death (flow cytometry).
  • Mechanism Mapping: Gene Set Enrichment Analysis (GSEA) was used to identify disrupted signaling pathways.
  • Drug Screening: Connectivity Map (Cmap) analysis was performed to predict small-molecule drugs that might target the HYAL2 pathway.

Results

Identification of HYAL2 as a Therapeutic Target

The initial bioinformatic screening revealed that among the six human hyaluronidases, only HYAL2 was consistently overexpressed in glioma tissues. Other enzymes in the family did not show similar patterns; for instance, HYAL1 was found to be downregulated in tumor samples compared to normal tissue.

Expression of HYAL1 in GBM and LGG showing downregulation in tumor tissue.

Similarly, HYAL4, HYALP1, and SPAM1 exhibited very low expression levels across the tested glioma datasets, further highlighting the specific metabolic dependency of these tumors on HYAL2.

Expression profiles of HYAL4, HYALP1, and SPAM1 in glioma datasets.

Clinical Correlation and Survival Impact

High HYAL2 expression was identified as an independent risk factor for poor patient outcomes. Univariate Cox analysis of the TCGA dataset yielded a Hazard Ratio (HR) of 2.527, indicating that high levels of the enzyme more than double the risk of mortality. Furthermore, HYAL2 levels were significantly higher in recurrent tumors compared to primary ones and correlated with IDH mutation status.

Cellular Mechanisms: Arrest and Apoptosis

Silencing HYAL2 led to a dramatic reduction in cancer cell colony formation. The study found that HYAL2 inhibition causes cell cycle arrest in the G1 phase, accompanied by a decrease in key regulatory proteins such as CCNB1 and CCND1. Additionally, knockdown shifted the cellular balance toward apoptosis by decreasing the anti-apoptotic protein Bcl-2 and increasing the pro-apoptotic protein BAX.

Potential Therapeutic Leads

Cmap analysis identified four potential drug candidates for repurposing: sphingosine, D-609, NVP-BGJ398, and itopride. D-609 is particularly noteworthy as it has previously demonstrated selective toxicity toward tumor cells in other cancer models.

Discussion

This study establishes HYAL2 as a critical driver of glioma progression through its role in HA catabolism. By "freezing" cell division and triggering apoptosis, HYAL2 inhibition represents a promising therapeutic avenue. However, the authors note that these findings currently rely on in vitro data. Future work must validate these mechanisms in animal models and test the efficacy of the identified small molecules in a living system. Characterizing the exact size and signaling properties of the HA fragments produced in the glioma microenvironment will also be essential for refining these targeted therapies.

Summary updated

Abstract

Collectively, these observations suggest that HYAL2 overexpression could promote glioma progression. Thus, treatments that disrupt HA catabolism by altering HYAL2 expression may serve as effective strategies for glioma treatment.
BibTeX
@inproceedings{yan2023inhibition,
  author = {Tao Yan and Yang He and Caixia Xu and Junsi Liu and Yun Meng and Qing Jiang and Jinxing Li and Guiqiong Kang and Liangjian Zhou and Shuai Xiao and Yanpeng Xue and Jiayi Xu and Xin Chen and Fengyuan Che},
  title = {{Inhibition of hyaluronic acid degradation pathway suppresses glioma progression by inducing apoptosis and cell cycle arrest}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1186/s12935-023-02998-4},
}
Figure